J S Perry

No ORCID on file · 3 papers in corpus
2026
Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial

Andrea S Lukes,1 Roberta Venturella,2 Krzysztof Dynowski,3 Rachel B Wagman,4 Julie S Perry,4 Yi Zhong,5 Viatcheslav G Rakov,6 Sylvia Mechsner,7 Neil P Johnson81Carolina Woman’s Research and Wellness Center, Durham, NC, USA; 2Department of C…

rct 2024
P-308 Relugolix combination therapy vs relugolix monotherapy with transition to relugolix combination therapy for the treatment of endometriosis-associated pain: implications for cumulative benefit/risk profile
·doi:10.1093/humrep/deae108.273

Abstract Study question How does the benefit/risk profile compare in women with endometriosis-associated pain who initiated relugolix combination therapy (Relugolix-CT) vs relugolix monotherapy with transition to Relugolix-CT? Summary answe…

rct 2023
O-032 Effect of relugolix combination therapy in women with endometriosis-associated pain who received prior first-line hormonal treatment: SPIRIT 1 and 2
·doi:10.1093/humrep/dead093.032

Abstract Study question To assess the effect of oral relugolix combination therapy (Relugolix-CT) in the subgroup of women with endometriosis-associated pain who received prior first-line hormonal treatment. Summary answer Relugolix-CT sign…